Biskup W, Calaminus G, Schneider D T, Leuschner I, Göbel U
Department of Pediatric Oncology, Hematology and Immunology, Children's-Hospital, UKD, Heinrich-Heine-University, Düsseldorf.
Klin Padiatr. 2006 Nov-Dec;218(6):303-8. doi: 10.1055/s-2006-942272.
The designation of a teratoma with malignant transformation (TMT) refers to the occurrence of somatic non-germ cell malignancies within a teratoma. While TMT is a rare but well recognised phenomenon in adult germ cell tumors (GCT), data on TMT in pediatric GCTs are lacking.
Between 1982 and 2003, 641 patients with extracranial nontesticular pure teratoma (256 coccygeal, 246 ovarian, 139 other sites) were reported to the MAKEI protocols 83/86/89/96 by various, mainly German centres. Patients with teratoma and somatic malignancy were identified by database queries. Patients with malignant germ cell tumor components were excluded from this analysis. The clinical files were reviewed and re-evaluated centrally. Information was actualized by requisition to the participating hospitals.
We identified nine patients (all female, age 0-39 years) meeting the histological criteria of TMT. Two patients had coccygeal teratomas and seven ovarian tumors. Carcinoma was the dominating malignancy (five of nine cases). Tumors with glial differentiation and embryonal tumors occurred in two cases each. Resection was performed in seven patients (including both coccygeal tumors) and adjuvant chemotherapy was administered in one of them. Two patients relapsed after resection, but both were cured with chemotherapy. Two patients suffered from advanced tumors and both were treated with primary chemotherapy. One patient was cured from the malignant component (astrocytoma), but the teratomatous components persisted. The other patient died as a result of progression of her malignant medulloepithelioma.
Malignant transformation of pure teratomas constitutes a very rare entity in children and adolescents that is most commonly observed in postpubertal girls with ovarian teratoma. Compared to adult patients, similar malignant entities can be observed in association with teratoma. However, in our series, no sarcoma was diagnosed. In localised tumors, complete resection appears to be adequate, whereas chemotherapy should be considered in patients with R1- or R2-resection. Cisplatinum-based chemotherapy was effective as two of four relapsed patients survived tumor free. However, the ideal regimen has not yet been established and the known sensitivity of the histologic components to cytostatic drugs has to be considered in the choice of treatment. Further molecular biologic studies are necessary to understand the origin of these tumors.
伴有恶性转化的畸胎瘤(TMT)是指在畸胎瘤内发生的体细胞非生殖细胞恶性肿瘤。虽然TMT在成人生殖细胞肿瘤(GCT)中是一种罕见但已得到充分认识的现象,但关于小儿GCT中TMT的数据却很缺乏。
1982年至2003年间,各主要是德国的中心向MAKEI方案83/86/89/96报告了641例颅外非睾丸纯畸胎瘤患者(256例尾骨畸胎瘤、246例卵巢畸胎瘤、139例其他部位畸胎瘤)。通过数据库查询确定患有畸胎瘤和体细胞恶性肿瘤的患者。本分析排除了具有恶性生殖细胞肿瘤成分的患者。对临床档案进行了回顾并集中重新评估。通过向参与医院索取资料更新信息。
我们确定了9例符合TMT组织学标准的患者(均为女性,年龄0 - 39岁)。2例患者患有尾骨畸胎瘤,7例患有卵巢肿瘤。癌是主要的恶性肿瘤(9例中有5例)。有胶质分化的肿瘤和胚胎性肿瘤各有2例。7例患者(包括2例尾骨肿瘤)进行了切除,其中1例接受了辅助化疗。2例患者切除后复发,但均通过化疗治愈。2例患者患有晚期肿瘤,均接受了一线化疗。1例患者的恶性成分(星形细胞瘤)治愈,但畸胎瘤成分持续存在。另1例患者因恶性髓上皮瘤进展而死亡。
纯畸胎瘤的恶性转化在儿童和青少年中是一种非常罕见的情况,最常见于青春期后患有卵巢畸胎瘤的女孩。与成年患者相比,与畸胎瘤相关的类似恶性实体也可观察到。然而,在我们的系列研究中,未诊断出肉瘤。对于局限性肿瘤,完整切除似乎就足够了,而对于R1或R2切除的患者应考虑化疗。基于顺铂的化疗是有效的,因为4例复发患者中有2例无瘤存活。然而,理想的治疗方案尚未确立,在选择治疗时必须考虑已知的组织学成分对细胞毒性药物的敏感性。需要进一步的分子生物学研究来了解这些肿瘤的起源。